Halozyme Therapeutics (NASDAQ: HALO) — Perfil da empresa, notícias e dados financeiros
Halozyme Therapeutics is a biotechnology firm focused on innovative oncology therapies and its proprietary ENHANZE® drug delivery technology.
Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company focused on developing and commercializing novel drug delivery technologies and specialty biopharmaceuticals. The company's primary proprietary platform, ENHANZE, utilizes a recombinant human hyaluronidase enzyme (rHuPH20) to temporarily degrade hyaluronan in the extracellular matrix, facilitating the rapid subcutaneous administration of biopharmaceutical products typically delivered intravenously. Halozyme licenses ENHANZE to major global pharmaceutical partners to co-formulate with commercial therapeutics across oncology, immunology, and rare disease therapeutic areas. Additionally, the company manufactures and markets advanced auto-injector and specialty drug delivery devices for subcutaneous self-administration of biologic drugs and small molecule therapeutics.
Resumo
Operações
Produtos e/ou serviços de Halozyme Therapeutics
- Drug Delivery Technology: Proprietary drug delivery platform utilizing recombinant human hyaluronidase enzyme to facilitate rapid subcutaneous delivery of co-formulated biopharmaceutical therapeutics, reducing patient infusion times and healthcare administration costs across multiple therapeutic areas globally.
- Oncology Partnered Products: Commercial licensing partnerships with global biopharmaceutical companies that integrate subcutaneous drug delivery enzyme technology into approved oncology biologics, generating recurring royalty revenues and milestone payments from large-volume injectable cancer treatments worldwide.
- Auto-Injector Delivery Systems: Engineering, development, and commercial supply of advanced high-volume auto-injectors and specialty drug-device combination products designed for patient self-administration of biopharmaceutical injectables and small-molecule medications across oncology and rare disease indications.
- Non-Oncology Biologic Formulations: Subcutaneous drug delivery licensing agreements covering non-oncology biopharmaceutical indications, enabling rapid injection of therapies for autoimmune, neurological, and rare diseases, including subcutaneous immunoglobulins and targeted monoclonal antibody therapies for international partner biopharmaceutical firms.
- Active Pharmaceutical Ingredient Supply: Bulk commercial manufacturing and supply of proprietary recombinant human hyaluronidase enzyme under strict quality control standards, delivering active pharmaceutical ingredients directly to drug manufacturing partners for co-formulation and finished drug product packaging.
- Biopharmaceutical Research and Development: Applied laboratory research and clinical formulation studies focused on expanding subcutaneous delivery capabilities, optimizing biologic formulation stability, evaluating potential therapeutic targets, and advancing next-generation drug delivery technologies for injectable specialty biopharmaceuticals.
equipe executiva do Halozyme Therapeutics
- Helen I. TorleyPresident, CEO & Director
- Mark SnyderExecutive VP, General Counsel, Chief Compliance Officer & Corporate Secretary
- Darren SnellgroveSenior VP & CFO
- Brian SweeneyChief Human Resources Officer
- David A. RamsayPresident of Drug Delivery
- Christopher WahlChief Scientific Officer
- Charles P. TheuerChief Medical Officer
- Paul SpenceChief Commercial Officer
- Rhys de CallierChief Strategy Officer
- Chase CoffmanPresident of Hypercon
Últimas notícias sobre a Halozyme Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Halozyme Therapeutics, em USD.
- Cap. de mercado
- 14,8 bi
- Receita (TTM)
- 1,7 bi
- P/L
- 38.0
- LPA (diluído, TTM)
- 3.4
- Dividend yield
- —
- Margem de lucro
- 24.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,4 bi | 802,6 mi | 316,9 mi | |
| 1 bi | 551,5 mi | 444,1 mi | |
| 829,3 mi | 337,6 mi | 281,6 mi | |
| 660,1 mi | 267,5 mi | 202,1 mi |